已发表论文

ALYREF  通过胶质母细胞瘤中的 ALYREF-MYC  正反馈环驱动癌细胞增殖

 

Authors Wang J, Li Y, Xu B, Dong J, Zhao H, Zhao D, Wu Y

Received 14 October 2020

Accepted for publication 24 December 2020

Published 8 January 2021 Volume 2021:14 Pages 145—155

DOI https://doi.org/10.2147/OTT.S286408

Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 3

Editor who approved publication: Dr Arseniy Yuzhalin

Background: While RNA-binding proteins (RBPs) are known to affect RNA homeostasis during cancer cell initiation and development, their characteristics and biological function in glioblastoma (GBM) remain unclear.
Methods: Differences in RBP expression were explored by differential analysis of The Cancer Genome Atlas-GBM and Genotype-Tissue Expression (GTEx) datasets. Real-time PCR was conducted to verify the expressional levels of Aly/REF export factor (ALYREF ) in normal brain and GBM tissues. Proliferative assays were performed to investigate molecular functions of ALYREF  in GBM cells in vitro and in vivo. Real-time PCR and Kyoto Encyclopedia of Genes and Genomes (KEGG) were performed to analyze the ALYREF  downstream signaling pathways. A chromatin immunoprecipitation (ChIP) assay was performed to identify key transcriptional factors that regulate ALYREF  expression at RNA level. UV crosslinking, immunoprecipitation (CLIP) and RNA stability assays were conducted to reveal the bound RNAs and their stability regulated by ALYREF .
Results: The results showed that ALYREF  is frequently increased in GBM tissues, and its mRNA expression is regulated by the MYC proto-oncogene, bHLH transcription factor (MYC ). Inhibition of ALYREF  expression decreased GBM cell proliferative ability in vitro and tumor formation in vivo. KEGG analysis revealed that high ALYREF  expression in GBM tissues was enriched in the upregulation of oncogenic pathways such as the Wnt/β-catenin signaling pathway. The CLIP assay showed that ALYREF  drives GBM carcinogenesis by binding to and stabilizing MYC  mRNAs. Overexpression of MYC  restored the oncogenic property of ALYREF -deficient GBM cells.
Conclusion: Our data showed that ALYREF  is regulated by MYC  at the transcriptional level. ALYREF  drives GBM cell proliferation by activating the Wnt/β-catenin signaling pathway and stabilizing MYC  mRNA, suggesting that an ALYREF-MYC  positive feedback loop might be a potential therapeutic target for treating GBM patients.
Keywords: RNA-binding protein, MYC, cell proliferation, GBM